Tonix Pharmaceuticals Files 8-K with Material Agreement
Ticker: TNXP · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1430306
Sentiment: neutral
Topics: material-agreement, filing, financials
Related Tickers: TNXP
TL;DR
TONX filed an 8-K on June 11, 2025, reporting a material definitive agreement and financial statements.
AI Summary
On June 11, 2025, Tonix Pharmaceuticals Holding Corp. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, with the company's principal executive offices located at 26 Main Street, Chatham, New Jersey.
Why It Matters
This filing indicates a significant business development for Tonix Pharmaceuticals, potentially impacting its operations and future strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided excerpt.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- June 11, 2025 (date) — Date of report
- 26 Main Street, Chatham, New Jersey 07928 (location) — Principal executive offices
- 2834 (sic_code) — Pharmaceutical Preparations
FAQ
What is the nature of the material definitive agreement filed by Tonix Pharmaceuticals?
The provided excerpt does not specify the details of the material definitive agreement, only that one was entered into on or before June 11, 2025.
When was this 8-K report filed?
The 8-K report was filed on June 11, 2025.
What is Tonix Pharmaceuticals Holding Corp.'s primary business classification?
Tonix Pharmaceuticals Holding Corp. is classified under Pharmaceutical Preparations with SIC code 2834.
Where are Tonix Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.
What is the company's state of incorporation and fiscal year end?
The company is incorporated in Nevada, and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).